Children who take part in this study will be offered treatment delivered by specialist CFS/ME therapists in both groups.
(And if FITNET-NHS is not effective?)If FITNET-NHS is effective, it may reduce NHS and wider costs to society, improve school attendance and quality of life, and change attitudes about paediatric CFS/ME being “untreatable” to being “treatable”.
There is a small risk that the study may recruit children that do not have CFS/ME but instead have other disorders that present with fatigue. To avoid this we have put in place rigorous tests to ensure that other causes of fatigue are diagnosed and referred for appropriate treatment. If children are recruited with fatigue and other disorders, the treatment approaches offered are sufficiently generic approaches to fatigue, they are likely to benefit to some extent.
stop criteria? more circles?An internal pilot study will be conducted with continuation of the trial based on achieving defined stop criteria.
Really!Q. Can you take part if you are severely affected by CFS/ME?
A. Yes, you can take part if you are severely affected. The therapists with adapt the treatment on the trial to suit your level of functioning.
Yes - remember with paediatric CFS being able to go to school for an hour a day counts as being severely affected...... not a clue.....Really!
...and still updating...
01/07/2019: The following changes were made:
1. The plain English summary was updated.
2. The contact details were updated.
3. The link to the participant information sheet was added.
4. The overall trial end date was updated from 30/10/2021 to 30/04/2022.
5. The target number of participants was updated from 734 to 314.
6. The recruitment end date was updated from 30/04/2020 to 31/10/2020.
7. The intention to publish date was updated from 30/10/2022 to 30/04/2023.
8. The sponsor contact details were updated.
09/07/2018: The following changes have been made:
1. The interventions have been changed.
2. The plain English summary has been changed.
04/09/2017: Ethics approval information added.
Interventions and Plain English summary have been updated.
stop criteria? more circles?
The stop criteria have been agreed with the Trial Steering Committee (TSC) prior to starting recruitment. The internal pilot study will not proceed to full trial if:
(1) the recruitment rate is substantially below target during the last 6 months of the internal pilot study and if the qualitative data suggests that we cannot improve recruitment by changing recruitment methods or
(2) the qualitative data suggests that the interventions are not acceptable to participants.
the recruitment rate is substantially below target during the last 6 months of the internal pilot study and if the qualitative data suggests that we cannot improve recruitment by changing recruitment methods
It took me quite a while to find the location where all versions of the protocol are collected:So they halved their target recruitment and gave themselves extra time in order to not be below target? [I've not checked those facts, just posting quickly off what was reported in this thread re recruitment]
In late 2018, it became clear that the recruitment rate would not allow us to achieve our secondary aims of testing the effectiveness and cost-effectiveness in children with CFS/ME and co-morbid mood disorders assuming the prevalence of co-morbid mood disorders was 30%.
We therefore: consulted with the TSC (28/11/2018), DSMC (10/10/2018 & by email report on 11/03/2019) and TMG (18/10/2018) and reviewed the trial with the funders (HTA) (10 th July 2018).
The primary aim for the full FITNET-NHS trial is the effectiveness of FITNET-NHS in children with CFS/ME (see objective 3, page 10). The trial was powered on a secondary outcome to test the effectiveness and cost effectiveness in children with CFS/ME and co-morbid mood disorders (see objective 4, page 10). This meant that to achieve 80% power to detect a 0.4SD difference at 5% significance, assuming 30% of children had a co-morbid mood disorder, we needed to randomise 734 children. This then provided 97% power at 1% significance to detect 0.35SD difference on the primary outcome (see paragraph 4.7.1)
In September 2018, we calculated the required sample size for the primary aim of effectiveness in children with CFS/ME as follows:
Data on 266 children will give us 90% power at 5% significance to detect a 0.4SD difference on the SF36-PFS. With attrition currently at approximately 15%, we will need to recruit 314 children. This is achievable (based on recruitment rates to date) by the end of October 2020. Hence our new recruitment target, which is now focussed on the primary analysis, is 314 children in total, 157 in each treatment group.
We considered the issue of co-morbid disorders.
On 02/10/2018, we investigated the rate of co-morbid mood disorders in FITNET-NHS participants. This was higher than our original estimates as the rate of co-morbid mood disorders was 40% (compared to 30% in our original estimates) meaning that the number of participants required to answer the secondary aim of efficacy in this group was 106 (53 in each treatment group).
After consultation with the HTA, TSC and DSMC, the decision was made by the TMG, on the 30 th of January 2019 to adjust the recruitment targets and extend the recruitment time by 6 months so that FITNET-NHS will be able to achieve the primary aim of testing the effectiveness and cost-effectiveness of FITNET-NHS compared to Activity Management. We will therefore recruit 314 children and recruitment will finish on 31 October 2020. Follow up will finish on 31 October 2021.
We are following standard procedure for updating HTA, Research Ethics Committee and trial registration (ISRCTN) regarding these changes.
For transparency, we have detailed changes to the flow chart, revised sample size calculation and recruitment targets below. HTA approval for revised recruitment target and the contract variation to include the 6-months extension to the project timeline was received on 24/04/2019 further subjected to ratification by the Department of Health and Social Care.
How about doing a trial on the effectiveness and cost-effectiveness of trials on the effectiveness and cost-effectiveness of interventions in ME?Cost: £1,026,403.00
So similar issues to HADS ?"This was higher than our original estimates as the rate of co-morbid mood disorders was 40%"
It is perhaps worth considering that some of the questionnaires used to quantify mood disorders in both adult and paediatric populations might cause their prevalence to be overestimated in ME patient cohorts. For example, the paediatric RCADS scale includes at least five questions that will likely be scored highly by ME patients regardless of the status of their mood: q11 ("I have trouble sleeping"); q19 ("I have no energy for things"); q21 ("I am tired a lot"); q25 ("I cannot think clearly"), and, for those with orthostatic tachycardia, q24 ("When I have a problem, my heart beats really fast").
Similar questions exist on the adult BDI-II: q15 (loss of energy); q16 (changes in sleeping pattern); q19 (concentration difficulty); q20 (tiredness or fatigue).
So they halved their target recruitment and gave themselves extra time in order to not be below target? [I've not checked those facts, just posting quickly off what was reported in this thread re recruitment]
How about doing a trial on the effectiveness and cost-effectiveness of trials on the effectiveness and cost-effectiveness of interventions in ME?
would love to see a break down of the costs to see how the money was spent.Cost: £1,026,403.00